Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs

Rappta Therapeutics (“Rappta”), focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A), announces today the closing of a EUR 9 million Series A financing co-led by Novartis Venture Fund (“NVF”) and Novo Holdings with participation from Advent Life Sciences and a family office. The company also announces it has successfully received funding from Business Finland, the Finnish innovation funding organization.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...